Tradestie Institutional Equity Comparison Engine

URGN vs XOMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XOMA Overall Edge

XOMA Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to XOMA Royalty Corporation Common Stock (XOMA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while URGN counters with relative strength in Valuation. Fundamentally, URGN trades at 10.2x Forward P/E with -12.4% operating margin (+223.9% YoY revenue) versus XOMA at 21.5x Forward P/E and -3.9% operating margin (-22.6% YoY). In options structure, URGN sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner URGN
URGN 10.2x vs XOMA 21.5x Fwd P/E
Growth & Margin Winner XOMA
Op Margin -12.4% vs -3.9% ยท YoY +223.9% vs -22.6%
Momentum & Technical Winner XOMA
1Y +18.8% vs +44.0% ยท 52W Pos 35% vs 78%
Options & Structure Winner XOMA
BREAKDOWN (10th %ile IV) vs UNCLASSIFIED (100th %ile IV)
URGN NASDAQ
UroGen Pharma Ltd. Ordinary Shares
Pharmaceutical Preparations
$28.41
+8.54% 1D
Market Cap $1.3B
1M Return -17.78%
1Y Return +18.79%
Forward P/E 10.2x
Unified AI Score
61.5 / 100 BUY
Tech 70.0 Fund 66.0 Flow 68.0 Mom 60.0
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
1M Return -3.81%
1Y Return +43.98%
Forward P/E 21.5x
Unified AI Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: URGN +18.79% XOMA +43.98% Spread: +40.58 pp (URGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
URGN TTM Op. Margin: -12.4% XOMA TTM Op. Margin: -3.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on URGN vs XOMA. Trailing 12-month operating profitability (URGN -12.4% vs XOMA -3.9%) and valuation multiples (URGN 10.2x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: URGN (5) vs XOMA (5)
Institutional Metric URGN XOMA Criterion Row Winner
Market Capitalization Scale $1.3B $781.8M Larger Scale URGN
Trailing P/E Ratio Valuation 12.9x 28.2x Lower Multiple URGN
Forward P/E Ratio Valuation 10.2x 21.5x Lower Multiple URGN
Revenue Growth (YoY) Growth +223.9% -22.6% Higher Growth URGN
Operating Margin (TTM) Profitability -12.4% -3.9% Higher Margin XOMA
Net Profit Margin Profitability -26.3% 69.6% Higher Margin XOMA
Return on Equity (ROE) Capital Efficiency -1481.3% 34.2% Higher ROE XOMA
52-Week Range Position Momentum 35% ($16โ€“$51) 78% ($22โ€“$45) Stronger Trend XOMA
Beta / 30D Volatility Risk Regime 1.33ฮฒ ยท 82% Vol 0.68ฮฒ ยท 37% Vol Lower Realized Risk XOMA
Unified Institutional Score Composite Signal 61.5 / 100 (BUY) 55.8 / 100 (HOLD) Higher Composite URGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full URGN vs XOMA Buy Guide
URGN BREAKDOWN
96d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live URGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live XOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither URGN nor XOMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.